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BACKGROUND: Aromatase inhibitors are widely used in the treatment of oestrogen receptor-positive post-menopausal breast cancer.
These patients may also be receiving the bisphosphonate, zoledronic acid (ZA) to prevent bone loss or reduce skeletal morbidity in
the setting of advanced disease. The potential biological interaction of these two drugs in breast cancer has not been assessed.
METHODS: Aromatase-expressing breast cancer cells were treated with letrozole and ZA either simultaneously or in sequence, and the
resulting apoptosis was assessed by staining with Hoechst 33342 and propidium iodide and examined using a fluorescent inverted
Leica DMIRB microscope and a UV filter.
RESULTS: We found that letrozole and ZA induce levels of apoptosis in breast cancer cells in vitro that are significantly greater
compared with treatment with each drug alone. However, this potentially, synergistic relationship is drug-sequence dependent,
occurring only when cells are treated with letrozole, followed by ZA. The converse sequence, or administering drugs simultaneously,
induces levels of apoptosis no greater than each drug alone.
CONCLUSION: Owing to the enhanced anti-tumour efficacy of sequential drug administration, our findings may indicate that, for
post-menopausal women who require treatment with letrozole, ZA should also be considered.
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Letrozole is a non-steroidal third-generation aromatase inhibitor
(AI) that binds to aromatase, which controls the last step in
oestrogen synthesis. The AIs induce a profound reduction in
oestradiol, oestrone and oestrone sulphate levels and, as a result,
inhibit the growth of oestrogen-dependent breast cancer. In post-
menopausal breast cancer, AIs are increasingly used in both
metastatic (Mouridsen et al, 2001) and adjuvant settings (BIG1-98
Collaborators 2009; Goss et al, 2005).
Breast cancer patients may also require bisphosphonate,
zoledronic acid (ZA) for various reasons. For example, letrozole
(as with other AIs) causes bone loss and increases the risk of
osteoporosis (Lester and Coleman, 2005). In addition, there is
growing evidence for an adjuvant function for bisposphonates in
early breast cancer (Gnant et al, 2009). Finally, patients may also
be receiving ZA for metastatic bone disease, to reduce skeletal
morbidity and pain (Rosen et al, 2001). As a result, increasing
numbers of patients are receiving both ZA and letrozole in
combination, either in early or advanced breast cancer. Table 1
lists current trials involving both ZA and letrozole in breast cancer
that are either actively recruiting patients or closed to recruitment,
but with results awaited.
The ZA is a potent nitrogen-containing bisphosphonate that
inhibits osteoclastic bone resorption (Green et al, 1994). All
nitrogen-containing bisphosphonates inhibit farnesyl pyrophos-
phate synthase in the mevalonate pathway (Dunford et al,
2001), leading to inhibition of farnesyl pyrophosphate and
geranylgeranyl pyrophosphate. These isoprenoids are required
for the post-translation lipid modification (i.e. farnesylation and
geranylgeranylation) of signalling GTPases, such as Ras, Rho and
Rac (Rogers et al, 2000). As these control a variety of important
osteoclast cell functions, their loss ultimately leads to osteoclast
apoptosis through caspase-3 enzyme activation (Benford et al,
2001).
In vitro, ZA also affects cancer cells directly through a wide
variety of mechanisms. These include induction of apoptosis,
inhibition of cancer cell growth, reduction of cancer cell adhesion,
invasion and anti-angiogenic effects. Many of these anti-tumour
effects are specifically related to inhibition of the mevalonate
pathway, with potential for even greater anti-tumour activity when
combined with other drugs (reviewed by Winter et al, 2008). To
date, the interactions between ZA and letrozole on breast cancer
cells in vitro have not been studied.
We have investigated whether ZA and letrozole, using cell
culture conditions that mimic the post-menopausal state, have
the potential for synergistic induction of apoptosis in breast cancer
cells in vitro, and present novel insights into the interaction
of ZA and the AI, letrozole.
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sMATERIALS AND METHODS
Tissue culture
To study the effect of letrozole in vitro, the human breast cancer
cell line, MCF7-Ca, was used (provided by Dr S Chen New York,
USA). This is an oestrogen receptor- and aromatase gene-expres-
sing breast cancer cell line. For experiments using ZA alone, cells
were routinely maintained in RPMI 1640 media, supplemented
with 10% foetal calf serum (FCS), glutamine (2mM) (all purchased
from Gibco, Invitrogen Corporation, Paisley, UK), penicillin
(100Uml
–1), streptomycin (100mgml
–1) (both purchased from
GlaxoSmithKline, Uxbridge, Middlesex, UK) and fungizone
(Amphoteracin B) (5mgml
–1) (Invitrogen Life Technologies Ltd,
Paisley, Renfrewshire, UK).
To mimic post-menopausal oestrogen levels, it was necessary to
deplete the medium of available oestrogen and add the aromatase
substrate, androstenedione (AD). Under these conditions the only
oestrogen available to cells would be through conversion of AD to
oestrogen by the aromatase enzyme. Therefore, cells were grown
and treated in phenol-red-free, glutamine-free RPMI 1640 media
(purchased from Gibco, Invitrogen Corporation), supplemented
with dextran-coated charcoal-stripped (from Sigma-Aldrich, Poole,
Dorset, UK) FCS. Phosphate-buffered solution (PBS) Dulbecco
and trypsin-EDTA (0.05% trypsin, 0.53mM EDTA.4Na in
Hanks-buffered saline solution) were supplied by Gibco (Invitrogen
Corporation). All plastics were purchased from Costar Ltd
(Bucks, UK).
Drugs and chemicals
The ZA ([1-hydroxy-2-(1H-imidazol-1-yl)ethylidene] bisphos-
phonic acid) was supplied as a disodium salt by Novartis (Basel,
Switzerland). A stock solution (10mM) was prepared in PBS and
stored at  201C. Letrozole was also a gift from Novartis and
supplied as a dry powder that was reconstituted in 100% ethanol
to make a 0.1 M stock solution, and stored at 4–81C. The stock
solution of each drug was diluted in appropriate culture media and
sterile filtered before use.
Geranylgeraniol (GGOH) (all trans-3, 7,11-15-tetramethyl-2,
6,10,14-hexadecatetraen-1-ol) and 4-androsten-3, 17-dione (AD)
were purchased from Sigma-Aldrich. Geranylgeraniol was diluted
in ethanol (1 M stock solution) and stored at  201C. For use in
experiments, it was diluted at least 20000-fold with culture media.
Androstenedione was supplied as 1mg dry powder, which was
serially diluted in ethanol. A concentration of 25nM was used for
Table 1 Current trials involving zoledronic acid in conjunction with letrozole, actively recruiting or results awaited, in breast cancer patients
Trial
identification Trial name Phase Sponsor
Number of
patients Status
NCT00050011 Zoledronic acid – letrozole adjuvant synergy trial (ZFAST) – cancer
treatment-related bone loss in post-menopausal women with
oestrogen receptor positive and/or progesterone receptor
positive breast cancer receiving adjuvant hormonal therapy
III Novartis 602 Active, not recruiting,
no results available
NCT00171314 The use of zoledronic acid to prevent cancer-treatment bone
loss in post-menopausal women receiving adjuvant letrozole
for breast cancer
III Novartis 500 Completed, results not
available as yet
NCT00171340 The use of zoledronic acid to prevent cancer-treatment bone
loss in post-menopausal women receiving adjuvant letrozole
for breast cancer
III Novartis 900 Completed, results not
available as yet
NCT00375752 Efficacy and safety of letrozole vs letrozole plus zoledronic acid
as endocrine therapy before surgery in post-menopausal
patients with breast cancer
II/III Novartis 860 Currently recruiting
NCT00332709 Safety/efficacy of letrozole monotherapy or in combination
with zoledronic acid as extended adjuvant treatment of
post-menopausal patients with primary breast cancer
III Novartis 460 Currently recruiting
NCT00247650 Randomized multi-centre study comparing prolonged
primary systemic endocrine therapy with letrozole alone or
in combination with zoledronic acid in early breast cancer
(neoadjuvant study in Canada)
II Novartis 190 Completed, no results
available
NCT00376740 Phase 3 study of the effect of zoledronic acid in the prevention
of osteoporosis in early breast cancer patients receiving the
aromatase inhibitor, letrozole, in the adjuvant setting
III Soroka University
Medical Center
80 Currently recruiting
NCT00114270 Evaluating the effect of letrozole with or without concomitant
zoledronic acid on oestrogen responsive targets in
post-menopausal women
III University of
Virginia
120 Active, not recruiting
NCT00107263 A randomized, controlled, open-label trial of empiric prophylactic
vs delayed use of zoledronic acid for prevention of bone loss
in post-menopausal women with breast cancer initiating therapy
with letrozole after tamoxifen
III North Central
Cancer
Treatment
Group
550 Active, not recruiting
NCT00412022 Phase III randomized study of the effects on bone mineral
density of tamoxifen, letrozole and letrozole + zoledronic
acid as adjuvant treatment of patients with early breast cancer
III National Cancer
Institute, Naples
500 Currently recruiting
NCT00436917 Zoledronic acid for treatment of osteopenia and osteoporosis
in women with primary breast cancer undergoing adjuvant
aromatase inhibitor (letrozole) therapy
Open-label Mayo Clinic 60 Active, not recruiting
NCT00903162 Extended endocrine therapy for pre-menopausal women with
breast cancer
Open-label Dana-Farber
Cancer Institute
50 Currently recruiting
NCT00072020 Does adjuvant zoledronic acid reduce recurrence in patients with
high-risk localised breast cancer? (AZURE)
a
III University of
Sheffield
3352 Awaiting results
aPatients may be also receiving chemotherapy or other endocrine agents, not exclusively letrozole, with or without zoledronic acid. Sources: UK clinical trials gateway
(http://www.controlled-trials.com) and Clinicaltrials.gov (http://www.clinicaltrials.gov.ct2/home).
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sexperiments on the basis of an earlier study by Professor A Brodie
(Thiantanawat et al, 2003).
Treatment of cells
Cells were seeded (at 20000/0.5ml per well) in 24-well plates and
incubated for 3 days (to confluence) before treatment. On the day
of treatment, cells were washed using 0.5ml of sterile PBS, and an
appropriate culture medium containing the drug(s) of interest was
added to the wells.
Proliferation assay
Cells (MCF7-Ca) were seeded in 24-well plates and treated
with either letrozole (0–100nM)o rZ A( 0 – 2 5mM), and at the end
of each specified incubation period, cells were counted using a
Coulter counter (Beckman Coulter, Z series).
Apoptosis assay
At the end of the specified drug treatment period, cells were
stained with 8mM Hoechst 33342 (Sigma RBI, Poole, Dorset, UK)
and 5mM propidium iodide (Molecular Probes, Cambridge
Biochemical, Cambridge, UK) for 15min at 371C. Both attached
and detached cells were stained and examined using a fluorescent
inverted Leica DMIRB microscope and a UV filter (355nm
excitation and 465nm emission). Propidium iodide was excluded
by viable cells, but stained the nuclei of necrotic cells. Hoechst
33342 entered the nuclei of viable and apoptotic cells, the latter
being recognised by characteristic features of karyorrhexis. The
incidence of viable, apoptotic and necrotic cells was obtained
by counting using a Whipple graticule in five separate random grid
areas in each of three wells for each treatment.
Experiments involving sequential administration of ZA
and letrozole
For these experiments, MCF7-Ca cells were seeded in 24-well
plates, and cells were treated with ZA (10mM) and letrozole
(100nM), each for 24h, alone and in combination, in oestrogen-
free media supplemented with AD (25nM), as follows (Figure 1
indicates the experiment design):
Group 1, ‘letrozole followed by ZA’: Cells were initially treated
with letrozole on day 1, and after 24h incubation (day 2), the
cells were washed and then treated with ZA for 24h until day 3.
At the end of 24h incubation with ZA, the cells were again washed
and incubated in fresh media (FM) for a further 24h, with cells
being assessed for apoptosis and necrosis on day 4.
Group 2, ‘ZA followed by letrozole’: Cells were initially treated
with ZA on day 1, and after 24h incubation (day 2), they were
Drug sequence 1
Letrozole off
zoledronic acid on Letrozole on Apoptotic cells counted Zoledronic acid off
Fresh medium
24 h 24 h
Day 1 Day 2 Day 3 Day 4
Day 1 Day 2 Day 3 Day 4
Day 1 Day 2 Day 3 Day 4
Drug sequence 2
Zoledronic acid
on
Zoledronic acid off
letrozole on Letrozole off
Apoptotic cells counted
Fresh medium
24 h 24 h 24 h
Drug sequence 3
Letrozole and
zoledronic acid
on
Apoptotic cells counted
Letrozole and
zoledronic acid off
Fresh medium
24 h 48 h
24 h
Figure 1 Experiment design for investigating the effects of sequential treatment of MCF7-Ca cells with letrozole (100nM) and zoledronic acid (25mM).
Drug sequence 1: ‘letrozole followed by zoledronic acid’; drug sequence 2: ‘zoledronic acid followed by letrozole’; drug sequence 3: ‘zoledronic acid and
letrozole together’).
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of 24h incubation with letrozole, the cells were again washed
and incubated in FM for a further 24h, with cells being assessed
for apoptosis and necrosis on day 4.
Group 3, ‘ZA and letrozole together’: Cells were treated with
ZA and letrozole, both administered together on day 1. After 24h
(day 2), cells were washed and further incubated in FM until day 4.
Control groups: Cells were treated with negative and positive
controls as follows:
with FM alone (days 1–4);
with ZA (days 1 and 2, added and removed at the same time as
ZA in group 2 or 3, and 1, respectively, and cells further incubated
in FM until day 4);
with letrozole (days 1 and 2, added and removed at the same
time as letrozole in group 1 or 3, and 2, respectively, and cells
further incubated in FM until day 4).
In all groups, cells were assessed for levels of viable, apoptotic
and necrotic cells on day 4, as detailed in the above section.
Statistical analysis
Statistical analysis was performed using SPSS 11 for Mac OS X.
For analysis of differences between means, one-way analysis
of variance or the Kruskal–Wallis test for non-parametric data
was used. Post hoc analysis was carried out using Tukey’s
HSD, Dunnett’s or the Games–Howell test, as appropriate. For
non-parametric data, post hoc analysis was performed using the
Mann–Whitney U-test, with a Bonferroni correction applied.
All experiments were repeated at least three times, and graphs
represent the mean of combined experiments with bars represent-
ing the s.e.m., unless otherwise indicated.
RESULTS
Effect of letrozole on the growth and survival of MCF7-Ca
breast cancer cells
The MCF7-Ca cells were grown and treated with letrozole
(0–100nM) for up to 72h in oestrogen-depleted media with
addition of AD. Only after 72h of treatment was there a significant
growth inhibition with 100nM (P¼0.001 vs control), whereas 24
and 48h of treatment with letrozole did not significantly inhibit
cell growth (Figure 2). Treatment of cells with letrozole for 72h,
however, resulted in a significant dose-dependent increase in the
percentage of apoptosis (Po0.0001) (Figure 2). A volume of 10 and
100nM of letrozole induced 10.7 and 18.1% apoptosis compared
with control levels of 7% (P¼0.47 and Po0.001, respectively). It is
interesting that, even with the highest concentration of letrozole,
the levels of necrosis were not significantly greater than those in
control samples, indicating that the mode of induced cell death of
letrozole under these conditions is apoptosis (Figure 3).
Effect of ZA on growth and survival of MCF7-Ca breast
cancer cells
In contrast to the growth-inhibitory effect of letrozole on MCF7-Ca
cells, exposing the cells to ZA (0–25mM) for only 1h induced
significant growth inhibition with as little as 1mM of ZA. This
caused a 35.8% reduction in cell proliferation, compared with that
in control (P¼0.0025). A similar growth-inhibitory effect was
obtained with 10mM (37.2% reduction in proliferation, P¼0.03)
and 25mM (5.2% reduction in proliferation, P¼0.005) (Figure 4).
To investigate the apoptosis-inducing effects of ZA, initial
experiments investigated the effect of ZA (0–25mM) treatment of
MCF7-Ca cells for 72h continuously. This induced a significant
concentration-dependent increase in apoptosis and necrosis, with
a maximal level of 21.4% (Po0.01) and 39.3% (Po0.01),
respectively, with 25mM (Figure 5A). Concentrations of at least
1mM of ZA induced a significant increase in apoptosis compared
with control, whereas a concentration of at least 10mM was
required to induce significant necrosis.
After a standard 4mg infusion of ZA, serum concentrations
rapidly fall within 1–2h as the drug localises to the bone (Chen
et al, 2002). When MCF7-Ca cells were treated with ZA (0–25mM)
for 1h, followed by a 72h incubation in FM, there was still a
concentration-dependent increase in apoptosis, compared with
control. Apoptosis that was significantly greater compared with
that in untreated controls occurred with at least 1mM. The maximal
apoptosis induced was 3.6% with 25mM of ZA (Po0.001, compared
with control). Significantly increased levels of necrosis were only
caused by the highest concentration of ZA (25mM) (4.7 vs 2% in
control, P¼0.011) (Figure 5B).
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Figure 2 Growth inhibition of MCF7-Ca cells treated with letrozole
(0–100nM) for 24–72h (*P¼0.001 vs control).
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Figure 3 Induction of apoptosis vs necrosis in MCF7-Ca cells after
treatment with letrozole (0–100nM) for 72h continuously in oestrogen-
free media (*Po0.05 and **Po0.001 vs control).
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sCollectively, these results indicate that MCF7-Ca cells are
sensitive to the apoptosis-inducing effects of ZA, even when used
for a short period of 1h. When extending the incubation period,
there is a significant increase in the levels of apoptosis, but with an
accompanying increase in necrotic cell death.
Effect of sequential ZA and letrozole on induction of
MCF7-Ca breast cancer cell apoptosis
We next investigated the combined effects of ZA and letrozole on
MCF7-Ca cells, and whether drug sequencing had any effect on the
levels of apoptosis. For these experiments, MCF7-Ca cells were
treated with ZA (10mM) and letrozole (100nM), each for 24h, alone
and in combination, in oestrogen-free media supplemented with
AD (25nM), as explained in the ‘Materials and Methods’ section.
As shown in Figure 6, increased levels of apoptosis occurred
when cells were treated with letrozole and ZA. However, this was
sequence dependent. Treating cells with letrozole, followed by ZA,
induced a level of apoptosis that was eight times greater than
treatment with letrozole alone (3.2 vs 0.4%, Po0.001) and nearly
five times greater than that with ZA alone (3.2 vs 0.7%, Po0.001)
(Figure 6A). However, treating cells with ZA, followed by letrozole,
induced only a total of 0.8% apoptosis, which was not significantly
greater than treatment with either drug alone (Figure 6B).
Similarly, treating cells simultaneously with ZA and letrozole
together induced only 0.4% apoptosis, again not significantly
greater than that with either drug alone (Figure 6C).
Finally, the sequence ‘letrozole then ZA’ induced significantly
more apoptosis than either the sequence ‘ZA then letrozole’
(Po0.001) or the sequence ‘ZA plus letrozole’ (Po0.001). In all
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Figure 5 (A) Induction of apoptosis vs necrosis in MCF7-Ca cells after treatment with zoledronic acid (0–25mM) for 72h continuously (*Po0.05 and
**Po0.01 vs control). (B) Induction of apoptosis vs necrosis in MCF7-Ca cells after treatment with zoledronic acid (0–25mM) for 1h (*Po0.05, **Pp0.01
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yPo0.001, compared with untreated controls).
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Figure 4 Growth inhibition of MCF7-Ca cells treated with zoledronic
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controls).
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sthree treatment groups (‘letrozole then ZA’, ‘ZA then letrozole’ and
‘ZA and letrozole together’), the levels of necrosis were not
significantly different compared with those in untreated controls.
In summary, these results indicate that when MCF7-Ca cells are
treated with letrozole and ZA in combination, only treating cells
sequentially with letrozole followed by ZA induces substantially
increased levels of apoptosis suggestive of synergy.
Effects of low, clinically relevant concentrations of ZA
As discussed earlier, ZA leaves the circulation rapidly after intra-
venous infusion to localise to the bone, with plasma peak levels
of around 1mM for 1h (Chen et al, 2002). Consequently, having
established that there is potential for enhanced levels of apoptosis
when breast cancer cells are treated with letrozole followed by ZA,
it was of interest to determine whether this effect could be achieved
using a concentration of ZA that more accurately reflects peak
circulating levels.
For initial experiments, MCF7-Ca cells were treated with
letrozole (100nM for 24h), and thereafter with 10mM of ZA for
1h only. We found that the resultant levels of apoptosis with
sequential treatment was five times greater than that with ZA alone
(4.0 vs 0.8%, P¼0.001), and three times greater than treatment with
letrozole alone (4.0 vs 1.3%, P¼0.01) (Figure 7). However, when
the concentration of ZA was further reduced to 1mM, treating
MCF7-Ca cells with letrozole (100nM for 24h) followed by 1mM ZA
for 1h, the effect of enhanced apoptosis was not observed, with the
resultant apoptosis being 1.3% and necrosis being 1.7%. In neither
case was this significantly greater than treatment with each drug
alone (data not shown). These results suggest a potentially
synergistic relationship. Though not reproducible using a very
low concentration of ZA, synergy is induced with 10mM, a concen-
tration that could be achieved within the bone microenvironment.
Function of the mevalonate pathway on ZA- and
letrozole-induced apoptosis
To assess whether increased levels of apoptosis induced by ZA
and letrozole in combination is, at least in part, due to inhibition
of the mevalonate pathway by ZA, the effect of the addition of
GGOH was investigated. Geranylgeraniol is a distal component
of the mevalonate pathway. If the mechanism of induced apoptosis
is through inhibition of this pathway, we would expect the levels
of apoptosis to be restored when GGOH is added to cells being
treated with ZA and letrozole. Cells (MCF7-Ca) were treated with
letrozole (100nM, 24h), and thereafter with ZA (10mM, 1h, with
or without 50mM GGOH, added and removed simultaneously
with ZA).
For cells treated with letrozole followed by ZA, the resultant
apoptosis was 4.0%, a level that was significantly greater than
that caused by letrozole alone (1.3%, P¼0.011), ZA alone (0.8%,
P¼0.001) or GGOH alone (0.3%, Po0.001) (Figure 8). The
addition of GGOH to cells treated with letrozole followed by ZA
reduced levels of apoptosis by 50% (2% with GGOH vs 4% without,
P¼0.05).
These results indicate that the increased level of apoptosis
obtained when cells are treated with letrozole followed by ZA is, in
part, through inhibition of the mevalonate pathway, as a
component of this pathway, GGOH, restores levels of apoptosis
by up to 50%.
DISCUSSION
We have evaluated the in vitro effects of different doses of
letrozole and ZA, alone and in combination, on MCF7-Ca cell
proliferation and apoptosis. As a single agent, letrozole alone
significantly inhibited the growth of cells only after 72h incubation
with the highest tested concentration (100nM). This suggests
that growth inhibition by letrozole in vitro is not as important as
the effects on apoptosis, as 100nM of letrozole induced up to 18%
apoptosis.
The ZA effectively inhibited the growth of these cells. Even just
1h of treatment (followed by a drug-free incubation period)
caused significant growth inhibition, with concentrations as low as
1mM. However, to detect this inhibitory effect, cells were incubated
in fresh medium for up to 72h after exposure to the drug. This
period is required for a turnover of (already) prenylated proteins
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Figure 7 The effect of drug sequencing with letrozole followed by ZA
on apoptosis when a clinically relevant concentration of ZA is used
(*Po0.01 for letrozole followed by ZA vs each drug alone).
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Figure 8 The effect of the mevalonate pathway intermediary,
geranylgeraniol (GGOH) (50mM), on the apoptosis induced by treatment
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sbefore inhibition of the mevalonate pathway by ZA (Neville-Webbe
et al, 2005) and subsequent apoptosis.
In combination, ZA and letrozole have potential for synergistic
induction of MCF7-Ca cells in vitro. However, increased induction
of apoptosis only occurred when cells were treated with letrozole
followed by ZA. ‘Letrozole then ZA’ induced a level of apoptosis
that was over eight times greater than that caused by letrozole
alone, and 4.8 times greater than treatment with ZA alone.
The ZA has consistently shown potential for synergistic inter-
action with drugs commonly used in breast cancer. This includes a
combination with paclitaxel (Jagdev et al, 2001; Neville-Webbe
et al, 2006), tamoxifen (Jagdev et al, 2000) and doxorubicin
(Neville-Webbe et al, 2005). In our earlier study with ZA and
chemotherapy drugs, we have similarly found that sequential
administration of drugs is of paramount importance for inducing
maximal (potentially synergistic) levels of apoptosis. For breast
cancer cells treated with ZA in combination with either doxo-
rubicin or paclitaxel, as with letrozole, cells had to be treated with
the chemotherapy drug first, and thereafter with ZA. Treating
cancer cells with the reverse sequence, or even simultaneously,
was either antagonistic or, at best, additive, and the same patterns
were seen here with letrozole. Our group recently evaluated this
sequence-dependent synergy in an in vivo soft-tissue breast
tumour model (Ottewell et al, 2008a,b). Using clinically relevant
doses of doxorubicin and ZA, inhibition of tumour growth was
shown to be sequence dependent with doxorubicin followed by ZA,
leading to inhibition of tumour growth associated with evidence
of enhanced tumour cell apoptosis and reduced proliferation.
The biological effects of letrozole and ZA are largely mediated
through the induction of apoptosis. It is likely that this is enhanced
through inhibition of the mevalonate pathway. Using an inter-
mediary of this pathway (GGOH), apoptosis was reduced by 50%
for cells treated with the sequence ‘ letrozole then ZA’. Inhibition
of the mevalonate pathway by nitrogen-bisphosphonates is integral
for inducing a variety of effects including apoptosis of osteoclasts
(Amin et al, 1992), breast cancer cells (Jagdev et al, 2001), prostate
cancer cells (Oades et al, 2003), myeloma cells (Shipman et al,
1998) and inhibition of tumour cell invasion (Denoyelle et al,
2003). Furthermore, inhibition of this pathway also contributes to
the apoptosis induced when breast (and prostate) cancer cells are
treated in combination with ZA and doxorubicin (Neville-Webbe
et al, 2005), or when breast cancer cells are treated with ZA and
paclitaxel (Neville-Webbe et al, 2006).
Although in vitro and in vivo studies have limited implications
for the clinical setting, it is interesting to note a recent update of
the ZO-FAST study (Eidtmann et al, 2008). This clinical trial
assesses the effects of ZA on letrozole-induced bone loss in post-
menopausal women with early breast cancer. Patients are
randomised to either combined letrozole and ZA (4mg every
6 months) or letrozole alone. A recent update, with a 36-month
follow-up, suggested a better outcome for those treated with the
combination, with a 41% risk reduction in cancer recurrence.
Although these results are preliminary, and the trial was not speci-
fically set up to address the anti-tumour potential of ZA in patients
receiving letrozole, they add to the growing evidence of the direct
anti-cancer effects of this bisphosphonate in combination with
other drugs, including endocrine treatments. Similarly, in the
ABCSG 12 trial of pre-menopausal breast cancer patients (Gnant
et al, 2009), 1803 patients received ovarian suppression with
goserelin and were then randomised to receive either tamoxifen or
the AI anastrazole, with or without ZA (4mg infusions every
6 months for 3 years). No significant differences in disease-free
survival were seen between tamoxifen and AI. However, the group
receiving ZA had a statistically significant 36% reduction in the risk
of disease recurrence, compared with patients receiving endocrine
therapy alone (P¼0.01). The reduction in metastatic events was not
confined to a reduction in the frequency of bone metastases alone,
but also applied to distant metastatic sites, loco-regional recurrence
rates and cancer of contralateral breast. Reduction of metastases
outside the skeleton adds to the growing evidence that the anti-
tumour effects of ZA are not confined to the bone, and such anti-
tumour effects may be enhanced by combination with other drugs.
In summary, letrozole has anti-tumour activity (which is largely
through induction of apoptosis) when used alone under culture-
media conditions that mimic the post-menopausal state. When
combined with ZA, there is potential for a synergistic induction of
apoptosis, but only when cancer cells are treated with letrozole
followed by ZA. This may have positive implications for post-
menopausal patients receiving both these drugs in the clinical
setting.
REFERENCES
Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE,
Perrone MH (1992) Bisphosphonates used for the treatment of bone
disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid
Res 33: 1657–1663
Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001)
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic
osteoclasts in vitro. Bone 28: 465–473
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P,
Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002)
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer
patients with bone metastases. J Clin Pharmacol 42: 1228–1236
Denoyelle C, Hong L, Vannier JP, Soria J, Soria C (2003) New insights
into the actions of bisphosphonate zoledronic acid in breast cancer
cells by dual RhoA-dependent and -independent effects. Br J Cancer 88:
1631–1640
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD,
Ebetino FH, Rogers MJ (2001) Structure-activity relationships for
inhibition of farnesyl diphosphate synthase in vitro and inhibition of
bone resorption in vivo by nitrogen-containing bisphosphonates.
J Pharmacol Exp Ther 296: 235–242
Eidtmann H, Bundred N, Deboer R, Llombart A, Davidson N, Neven P,
von Minckwitz G, Miller J, Schenk N, Coleman R (2008) The effect of
zoledronic acid on aromatase inhibitor associated bone loss in
postmenopausal women with early breast cancer receiving adjuvant
letrozole: 36 months follow-up of ZO-FAST. CTRC-AACR San Antonio
Breast Cancer Symposium 69: Abstract 44
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G,
Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V,
Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P,
Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, March C (2009)
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
NE n g lJM e d360: 679–691
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M,
Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE,
Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL
(2005) Randomized trial of letrozole following tamoxifen as extended
adjuvant therapy in receptor-positive breast cancer: updated findings from
NCIC CTG MA.17. J Natl Cancer Inst 97: 1262–1271
Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP
420446, a new, potent, heterocyclic bisphosphonate compound. J Bone
Miner Res 9: 745–751
Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI (2001) The
bisphosphonate, zoledronic acid, induces apoptosis of breast cancer
cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126–1134
Jagdev SP, Croucher P, Coleman RE (2000) Zoledronate induces apoptosis
of breast cancer cells in vitro-evidence for additive and synergistic effects
with taxol and tamoxifen. Proceedings of American Society of Clinical
Oncology (ASCO) 49: abstract 2619
Synergistic interaction between ZA and letrozole in breast cancer
HL Neville-Webbe et al
1016
British Journal of Cancer (2010) 102(6), 1010–1017 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sLester J, Coleman R (2005) Bone loss and the aromatase inhibitors. Br J
Cancer 93(Suppl 1): S16–S22
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier
A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A,
Dank M, Becquart D, Bapsy P, Salminen E, Snyder R, Lassus M,
Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior
efficacy of letrozole versus tamoxifen as first-line therapy for post-
menopausal women with advanced breast cancer: results of a phase III
study of the International Letrozole Breast Cancer Group. J Clin Oncol
19: 2596–2606
Neville-Webbe HL, Evans CA, Coleman RE, Holen I (2006) Mechanisms of
the synergistic interaction between the bisphosphonate zoledronic acid
and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
Tumour Biol 27: 92–103
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I
(2005) Sequence- and schedule-dependent enhancement of zoledronic
acid induced apoptosis by doxorubicin in breast and prostate cancer
cells. Int J Cancer 13: 364–371
Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW (2003) Nitrogen
containing bisphosphonates induce apoptosis and inhibit the mevalonate
pathway, impairing Ras membrane localization in prostate cancer cells.
J Urol 170: 246–252
Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P,
Holen I (2008a) Differential effect of doxorubicin and zoledronic acid
on intraosseous versus extraosseous breast tumor growth in vivo.
Clin Cancer Res 14: 4658–4666
Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE,
Holen I (2008b) Antitumor effects of doxorubicin followed by
zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst
100: 1167–1178
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J,
Frith JC (2000) Cellular and molecular mechanisms of action of
bisphosphonates. Cancer 88: 2961–2978
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J,
Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ,
Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the
treatment of skeletal metastases in patients with breast cancer or
osteolytic lesions of multiple myeloma: a phase III, double blind,
comparative trial. Cancer J 7: 377–387
Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ (1998)
The bisphosphonate incadronate (YM175) causes apoptosis of human
myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res
58: 5294–5297
Thiantanawat A, Long BJ, Brodie AM (2003) Signaling pathways of
apoptosis activated by aromatase inhibitors and antiestrogens. Cancer
Res 63: 8037–8050
Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity
of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453–475
Synergistic interaction between ZA and letrozole in breast cancer
HL Neville-Webbe et al
1017
British Journal of Cancer (2010) 102(6), 1010–1017 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s